Helmholtz Gemeinschaft


Browse by Research Team

Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Source
Jump to: 2023 | 2022 | 2021 | 2020 | 2019 | 2016 | 2015 | 2014 | 2013


Cardiovascular and metabolic determinants of quality of life in patients with cancer.
Evertz, R. and Gödde, K. and Diehl, C. and Valentova, M. and Garfias-Veitl, T. and Braulke, F. and Wulf, G.G. and Overbeck, T.R. and Bleckmann, A. and König, A.O. and Weinländer, P. and Potthoff, S. and Hadzibegovic, S. and Lena, A. and Keller, U. and Landmesser, U. and Schuster, A. and Anker, M.S. and Hasenfuß, G. and von Haehling, S.
ESC Heart Failure 10 (1): 167-176. February 2023


Relapse of NPM1-mutated AML with extramedullary manifestation 17 years after allogeneic hematopoietic stem cell transplantation.
Braune, J. and Rieger, K. and Blau, O. and Keller, U. and Bullinger, L. and Krönke, J.
Case Reports in Hematology 2022 : 3317936. 28 December 2022

The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myeloma.
Paulmann, C. and Spallek, R. and Karpiuk, O. and Heider, M. and Schäffer, I. and Zecha, J. and Klaeger, S. and Walzik, M. and Öllinger, R. and Engleitner, T. and Wirth, M. and Keller, U. and Krönke, J. and Rudelius, M. and Kossatz, S. and Rad, R. and Kuster, B. and Bassermann, F.
EMBO Journal 41 (20): e110871. 17 October 2022

Small molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.
Demel, U.M. and Wirth, M. and Yousefian, S. and Zhang, L. and Isaakidis, K. and Dönig, J. and Böger, M. and Singh, N. and Köse, H. and Haas, S. and Müller, S. and Schick, M. and Keller, U.
Haematologica 22 September 2022 (In Press)

Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany.
Braitsch, K. and Schmalbrock, L.K. and Jung, P. and Bumeder, I. and Kiewe, P. and Hecker, J.S. and Verbeek, M. and Westermann, J. and Bullinger, L. and Keller, U. and Bassermann, F. and Krönke, J. and Götze, K.S. and Rieger, K.
HemaSphere 6 (9): e759. September 2022

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis.
Kraus, S. and Klassen, P. and Kircher, M. and Dierks, A. and Habringer, S. and Gäble, A. and Kortüm, K.M. and Weinhold, N. and Ademaj-Kospiri, V. and Werner, R.A. and Schirbel, A. and Buck, A.K. and Herhaus, P. and Wester, H.J. and Rosenwald, A. and Weber, W.A. and Einsele, H. and Keller, U. and Rasche, L. and Lapa, C.
Theranostics 12 (13): 5986-5994. 8 August 2022

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen, G.J.J.E. and Baumgartner, F. and Heider, M. and Patra, U. and Holz, M. and Braune, J. and Kaiser, M. and Schäffer, I. and Bamopoulos, S.A. and Ramberger, E. and Murgai, A. and Ng, Y.L.D. and Demel, U.M. and Laue, D. and Liebig, S. and Krüger, J. and Janz, M. and Nogai, A. and Schick, M. and Mertins, P. and Müller, S. and Bassermann, F. and Krönke, J. and Keller, U. and Wirth, M.
Blood Advances 2 August 2022 (In Press)

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri, A.J.M. and Cwynarski, K. and Pulczynski, E. and Fox, C.P. and Schorb, E. and Celico, C. and Falautano, M. and Nonis, A. and La Rosée, P. and Binder, M. and Fabbri, A. and Ilariucci, F. and Krampera, M. and Roth, Al. and Hemmaway, C. and Johnson, P.W. and Linton, K.M. and Pukrop, T. and Gørløv, J.S. and Balzarotti, M. and Hess, G. and Keller, U. and Stilgenbauer, S. and Panse, J. and Tucci, A. and Orsucci, L. and Pisani, F. and Zanni, M. and Krause, S.W. and Schmoll, H.J. and Hertenstein, B. and Rummel, M. and Smith, J. and Thurner, L. and Cabras, G. and Pennese, E. and Ponzoni, M. and Deckert, M. and Politi, L.S. and Finke, J. and Ferranti, A. and Cozens, K. and Burger, E. and Ielmini, N. and Cavalli, F. and Zucca, E. and Illerhaus, G.
Leukemia 36 (7): 1870-1878. July 2022

Gene gun Her2/neu DNA vaccination: evaluation of vaccine efficacy in a syngeneic Her2/neu mouse tumor model.
Nguyen-Hoai, T. and Hohn, O. and Pezzutto, A. and Westermann, J.
Methods in Molecular Biology 2521 (3): 129-154. 23 June 2022

TCR gene therapy for cancer.
Rhein, S. and Çakmak-Görür, N.
Methods in Molecular Biology 2521 (3): 95-128. 23 June 2022

Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia.
Hegazy, A.N. and Krönke, J. and Angermair, S. and Schwartz, S. and Weidinger, C. and Keller, U. and Treskatsch, S. and Siegmund, B. and Schneider, T.
BMC Infectious Diseases 22 (1): 537. 13 June 2022

Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Braitsch, K. and Schwarz, A. and Koch, K. and Hubbuch, M. and Menzel, H. and Keller, U. and Götze, K.S. and Bassermann, F. and Herhaus, P. and Verbeek, M.
Annals of Hematology 101 (6): 1311-1319. June 2022

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
Demel, U.M. and Böger, M. and Yousefian, S. and Grunert, C. and Zhang, L. and Hotz, P.W. and Gottschlich, A. and Köse, H. and Isaakidis, K. and Vonficht, D. and Grünschläger, F. and Rohleder, E. and Wagner, K. and Dönig, J. and Igl, V. and Brzezicha, B. and Baumgartner, F. and Habringer, S. and Löber, J. and Chapuy, B. and Weidinger, C. and Kobold, S. and Haas, S. and Busse, A.B. and Müller, S. and Wirth, M. and Schick, M. and Keller, U.
Journal of Clinical Investigation 132 (9): e152383. 2 May 2022

Isolation of neoantigen-specific human T cell receptors from different human and murine repertoires.
Grunert, C. and Willimsky, G. and Peuker, C.A. and Rhein, S. and Hansmann, L. and Blankenstein, T. and Blanc, E. and Beule, D. and Keller, U. and Pezzutto, A. and Busse, A.
Cancers 14 (7): 1842. 6 April 2022

A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior.
Wasilewski, D. and Janz, M. and Koch, A. and Rosenwald, A. and Keller, U. and Vajkoczy, P. and Faust, K. and Anagnostopoulos, I. and Radke, J.
Acta Neurologica Belgica 2 April 2022 (In Press)

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Hess, G. and Hüttmann, A. and Witzens-Harig, M. and Dreyling, M.H. and Keller, U. and Marks, R. and Ernst, T. and Pott, C. and Viardot, A. and Frontzek, F. and Trautmann, M. and Ruckes, C. and Deuster, O. and Rosenwald, A. and Theobald, M. and Lenz, G.
British Journal of Haematology 198 (3): 482-491. 1 April 2022

90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Rieger, K. and De Filippi, R. and Lindén, O. and Viardot, A. and Hess, G. and Lerch, K. and Neumeister, P. and Stroux, A. and Peuker, C.A. and Pezzutto, A. and Pinto, A. and Keller, U. and Scholz, C.W.
Annals of Hematology 101 (4): 781-788. April 2022

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer.
Doffo, J. and Bamopoulos, S.A. and Köse, H. and Orben, F. and Zang, C. and Pons, M. and den Dekker, A.T. and Brouwer, R.W.W. and Baluapuri, A. and Habringer, S. and Reichert, M. and Illendula, A. and Krämer, O.H. and Schick, M. and Wolf, E. and van IJcken, W.F.J. and Esposito, I. and Keller, U. and Schneider, G. and Wirth, M.
Proceedings of the National Academy of Sciences of the United States of America 119 (9): e2105691119. 1 March 2022

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng, Y.L.D. and Ramberger, E. and Bohl, S.R. and Dolnik, A. and Steinebach, C. and Conrad, T. and Müller, S. and Popp, O. and Kull, M. and Haji, M. and Gütschow, M. and Döhner, H. and Walther, W. and Keller, U. and Bullinger, L. and Mertins, P. and Krönke, J.
Nature Communications 13 (1): 1009. 23 February 2022

Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Kaddu-Mulindwa, D. and Lesan, V. and Berdel, C. and Stilgenbauer, S. and Bewarder, M. and Thurner, L. and Witzens-Harig, M. and Viardot, A. and Soekler, M. and Keller, U. and Truemper, L. and Christofyllakis, K. and Fleser, O. and Bittenbring, J.T. and Poeschel, V. and Held, G. and Jagoda, P.
Leukemia & Lymphoma 63 (2): 326-334. February 2022

Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
Peuker, C.A. and Yaghobramzi, S. and Grunert, C. and Keilholz, L and Gjerga, E. and Hennig, S. and Schaper, S. and Na, I.K. and Keller, U. and Brucker, S. and Decker, T. and Fasching, P. and Fehm, T. and Janni, W. and Kümmel, S. and Schneeweiss, A. and Schuler, M. and Lüftner, D. and Busse, A.
European Journal of Cancer 162 : 45-55. February 2022

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh, J. and Seckinger, A. and Heider, M. and Rudelius, M. and Eichner, R. and Schick, M. and Slawska, J. and Emde, M. and Salwender, H. and Bertsch, U. and Goldschmidt, H. and Weisel, K.C. and Scheid, C. and Keller, U. and Hose, D. and Bassermann, F.
Blood Advances 6 (2): 515-520. 25 January 2022

Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma.
Schick, M. and Zhang, L. and Maurer, S. and Maurer, H.C. and Isaakaidis, K. and Schneider, L. and Patra, U. and Schunck, K. and Rohleder, E. and Hofstetter, J. and Baluapuri, A. and Scherger, A.K. and Slotta-Huspenina, J. and Hettler, F. and Weber, J. and Engleitner, T. and Maresch, R. and Slawska, J. and Lewis, R. and Istvanffy, R. and Habringer, S. and Steiger, K. and Baiker, A. and Oostendorp, R.A.J. and Miething, C. and Lenhof, H.P. and Bassermann, F. and Chapuy, B. and Wirth, M. and Wolf, E. and Rad, R. and Müller, S. and Keller, U.
Nature Communications 13 (1): 281. 12 January 2022

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker, S. and Bittner, A. and Frick, M. and Kase, J. and Hoffmann, J. and Trenker, C. and Keller, U. and Bogner, C. and Hüttmann, A. and Dürig, J. and Janz, M. and Mathas, S. and Marks, R. and Krohn, U. and Na, I.K. and Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 63 (1): 84-92. January 2022


Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study.
Kayser, S. and Schlenk, R.F. and Lebon, D. and Carre, M. and Götze, K.S. and Stölzel, F. and Berceanu, A. and Schäfer-Eckart, K. and Peterlin, P. and Hicheri, Y. and Rahme, R. and Raffoux, E. and Chermat, F. and Krause, S.W. and Aulitzky, W.E. and Rigaudeau, S. and Noppeney, R. and Berthon, C. and Görner, M. and Jost, E. and Carassou, P. and Keller, U. and Orvain, C. and Braun, T. and Saillard, C. and Arar, A. and Kunzmann, V. and Wemeau, M. and De Wit, M. and Niemann, D. and Bonmati, C. and Schwänen, C. and Abraham, J. and Aljijakli, A. and Haiat, S. and Krämer, A. and Reichle, A. and Gnadler, M. and Willekens, C. and Spiekermann, K. and Hiddemann, W. and Müller-Tidow, C. and Thiede, C. and Röllig, C. and Serve, H. and Bornhäuser, M. and Baldus, C.D. and Lengfelder, E. and Fenaux, P. and Platzbecker, U. and Adès, L.
Haematologica 106 (12): 3100-3106. December 2021

Survey of long-term experiences of sperm cryopreservation in oncological and non-oncological patients: usage and reproductive outcomes of a large monocentric cohort.
Lackamp, N. and Wilkemeyer, I. and Jelas, I. and Keller, U. and Bullinger, L. and Stintzing, S. and le Coutre, P.
Frontiers in Oncology 11 : 772809. 5 November 2021

Rationale for MYC imaging and targeting in pancreatic cancer.
Schneider, G. and Wirth, M. and Keller, U. and Saur, D.
EJNMMI Research 11 (1): 104. 12 October 2021

CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
Lewis, R. and Maurer, H.C. and Singh, N. and Gonzalez-Menendez, I. and Wirth, M. and Schick, M. and Zhang, L. and Isaakidis, K. and Scherger, A.K. and Schulze, V. and Lu, J. and Zenz, T. and Steiger, K. and Rad, R. and Quintanilla-Martinez, L. and Espeli, M. and Balabanian, K. and Keller, U. and Habringer, S.
Leukemia 35 : 2895-2905. October 2021

The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum (R-DHAP) for the treatment of patients with relapsed or refractory DLBCL - results from the phase-II STORM trial.
Witzens-Harig, M. and Viardot, A. and Keller, U. and Wosniok, J. and Deuster, O. and Klemmer, J. and Geueke, A.M. and Meißner, J. and Ho, A.D. and Atta, J. and Marks, R. and La Rosée, P. and Buske, C. and Dreyling, M.H. and Hess, G.
HemaSphere 5 (10): e636. October 2021

Investigation of spleen CXCR4 expression by [(68)Ga]Pentixafor PET in a cohort of 145 solid cancer patients.
Lewis, R. and Habringer, S. and Kircher, M. and Hefter, M. and Peuker, C.A. and Werner, R. and Ademaj-Kospiri, V. and Gäble, A. and Weber, W. and Wester, H.J. and Buck, A. and Herhaus, P. and Lapa, C. and Keller, U.
EJNMMI Research 11 (1): 77. 21 August 2021

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar, Ö. and Brzezicha, B. and Grunert, C. and Kloetzel, P.M. and Beier, C. and Peuker, C.A. and Keller, U. and Pezzutto, A. and Busse, A.
Journal for ImmunoTherapy of Cancer 9 (7): e002410. 30 July 2021

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers, N. and Duell, J. and Fitzgerald, D. and Kerkhoff, A. and Noerenberg, D. and Kaebisch, E. and Acker, F. and Fuhrmann, S. and Leng, C. and Welslau, M. and Chemnitz, J. and Middeke, J.M. and Weber, T. and Holtick, U. and Trappe, R. and Pfannes, R. and Liersch, R. and Spoer, C. and Fuxius, S. and Gebauer, N. and Caillé, L. and Geer, T. and Koenecke, C. and Keller, U. and Claus, R. and Mougiakakos, D. and Mayer, S. and Huettmann, A. and Pott, C. and Trummer, A. and Wulf, G. and Brunnberg, U. and Bullinger, L. and Hess, G. and Mueller-Tidow, C. and Glass, B. and Lenz, G. and Dreger, P. and Dietrich, S.
Blood Advances 5 (13): 2707-2716. 13 July 2021

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl, S. and Goergen, H. and Buehnen, I. and Kobe, C. and Moccia, A. and Greil, R. and Eichenauer, D.A. and Zijlstra, J.M. and Markova, J. and Meissner, J. and Feuring-Buske, M. and Soekler, M. and Beck, H.J. and Willenbacher, W. and Ludwig, W.D. and Pabst, T. and Topp, M.S. and Hitz, F. and Bentz, M. and Keller, U.B. and Kühnhardt, D. and Ostermann, H. and Hertenstein, B. and Aulitzky, W. and Maschmeyer, G. and Vieler, T. and Eich, H. and Baues, C. and Stein, H. and Fuchs, M. and Diehl, V. and Dietlein, M. and Engert, A. and Borchmann, P.
Lancet Haematology 8 (6): e398-e409. June 2021

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Schmitz, N. and Truemper, L.H. and Bouabdallah, K. and Ziepert, M. and Leclerc, M. and Cartron, G. and Jaccard, A. and Reimer, P. and Wagner-Drouet, E.M. and Wilhelm, M. and Sanhes, L. and Lamy, T. and de Leval, L. and Rosenwald, A. and Roussel, M. and Kroschinsky, F.P. and Lindemann, W.W. and Dreger, P. and Viardot, A. and Milpied, N.J. and Gisselbrecht, C. and Wulf, G.G. and Gyan, E. and Gaulard, P. and Bay, J.O. and Glass, B. and Poeschel, V. and Damaj, G. and Sibon, D. and Delmer, A.J. and Bilger, K. and Banos, A. and Haenel, M. and Dreyling, M. and Metzner, B. and Keller, U. and Braulke, F. and Friedrichs, B. and Nickelsen, M. and Altmann, B. and Tournilhac, O.
Blood 137 (19): 2646-2656. 13 May 2021

Spontaneous non-sustained ventricular tachycardia and premature ventricular contractions and their prognostic relevance in patients with cancer in routine care.
Albrecht, A. and Porthun, J. and Eucker, J. and Coats, A.J.S. and von Haehling, S. and Pezzutto, A. and Karakas, M. and Riess, H. and Keller, U. and Landmesser, U. and Haverkamp, W. and Anker, S.D. and Anker, M.S.
Cancers 13 (10): 2303. 12 May 2021

High-dose glucocorticoid treatment of near-fatal Bocavirus lung infection results in rapid recovery.
Obenaus, M. and Schildgen, O. and Schürmann, D. and von Brünneck, A.C. and Janz, M. and Keller, U. and Gebauer, B. and Schilling, J. and Schwartz, S. and Weissbrich, B. and Schneider, T. and Hofmann, J. and Mathas, S.
ERJ Open Research 7 (2): 00060-2021. 12 April 2021

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
Heider, M. and Eichner, R. and Stroh, J. and Morath, V. and Kuisl, A. and Zecha, J. and Lawatscheck, J. and Baek, K. and Garz, A.K. and Rudelius, M. and Deuschle, F.C. and Keller, U. and Lemeer, S. and Verbeek, M. and Götze, K.S. and Skerra, A. and Weber, W.A. and Buchner, J. and Schulman, B.A. and Kuster, B. and Fernández-Sáiz, V. and Bassermann, F.
Molecular Cell 81 (6): 1170-1186. 18 March 2021

ECG scoring for the evaluation of therapy-naïve cancer patients to predict cardiotoxicity.
Pohl, J. and Mincu, R.I. and Mrotzek, S.M. and Wakili, R. and Mahabadi, A.A. and Potthoff, S.K. and Siveke, J.T. and Keller, U. and Landmesser, U. and Rassaf, T. and Anker, M.S. and Totzeck, M.
Cancers 13 (6): 1197. 10 March 2021

The SUMO pathway in pancreatic cancer: insights and inhibition.
Schneeweis, C. and Hassan, Z. and Schick, M. and Keller, U. and Schneider, G.
British Journal of Cancer 124 (3): 531-538. 2 February 2021

Assessment of coronary artery disease during hospitalization for cancer treatment.
Mrotzek, S.M. and Lena, A. and Hadzibegovic, S. and Ludwig, R. and Al-Rashid, F. and Mahabadi, A.A. and Mincu, R.I. and Michel, L. and Johannsen, L. and Hinrichs, L. and Schuler, M. and Keller, U. and Anker, S.D. and Landmesser, U. and Rassaf, T. and Anker, M.S. and Totzeck, M.
Clinical Research in Cardiology 110 (2): 200-210. February 2021

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann, P. and Plütschow, A. and Kobe, C. and Greil, R. and Meissner, J. and Topp, M.S. and Ostermann, H. and Dierlamm, J. and Mohm, J. and Thiemer, J. and Sökler, M. and Kerkhoff, A. and Ahlborn, M. and Halbsguth, T.V. and Martin, S. and Keller, U. and Balabanov, S. and Pabst, T. and Vogelhuber, M. and Hüttmann, A. and Wilhelm, M. and Zijlstra, J.M. and Moccia, A. and Kuhnert, G. and Bröckelmann, P.J. and von Tresckow, B. and Fuchs, M. and Klimm, B. and Rosenwald, A. and Eich, H. and Baues, C. and Marnitz, S. and Hallek, M. and Diehl, V. and Dietlein, M. and Engert, A.
Lancet Oncology 22 (2): 223-234. February 2021

Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial.
Voltin, C.A. and Mettler, J. and van Heek, L. and Goergen, H. and Müller, H. and Baues, C. and Keller, U. and Meissner, J. and Trautmann-Grill, K. and Kerkhoff, A. and Fuchs, M. and Sasse, S. and von Tresckow, B. and Dietlein, M. and Borchmann, P. and Engert, A. and Kobe, C. and Bröckelmann, P.J.
Clinical Cancer Research 27 (2): 402-407. January 2021


Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke, S. and Bröckelmann, P.J. and Iaccarino, I. and Garcia-Marquez, M. and Borchmann, S. and Jochims, F. and Kotrova, M. and Pal, K. and Brüggemann, M. and Hartmann, E. and Sasse, S. and Kobe, C. and Mathas, S. and Soekler, M. and Keller, U. and Bormann, M. and Zimmermann, A. and Richter, J. and Fuchs, M. and von Tresckow, B. and Borchmann, P. and Schlößer, H. and von Bergwelt-Baildon, M. and Rosenwald, A. and Engert, A. and Klapper, W.
Blood 136 (25): 2851-2863. 17 December 2020

Ubiquitination and ubiquitin-like modifications in multiple myeloma: biology and therapy.
Wirth, M. and Schick, M. and Keller, U. and Krönke, J.
Cancers 12 (12): 3764. 14 December 2020

Authentication of primary murine cell lines by a microfluidics-based lab-on-chip system.
Hong, Y. and Singh, N. and Bamopoulos, S. and Gjerga, E. and Schmalbrock, L.K. and Balabanian, K. and Schick, M. and Keller, U. and Wirth, M.
Biomedicines 8 (12): 590. 9 December 2020

CXCR4-targeted PET imaging of central nervous system B-cell lymphoma.
Herhaus, P. and Lipkova, J. and Lammer, F. and Yakushev, I. and Vag, T. and Slotta-Huspenina, J. and Habringer, S. and Lapa, C. and Pukrop, T. and Hellwig, D. and Wiestler, B. and Buck, A.K. and Deckert, M. and Wester, H.J. and Bassermann, F. and Schwaiger, M. and Weber, W.A. and Menze, B. and Keller, U.
Journal of Nuclear Medicine 61 (12): 1765-1771. 1 December 2020

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A - results of a retrospective analysis.
Pouyiourou, M. and Meyer, A. and Stroux, A. and Viardot, A. and La Rosée, P. and Maschmeyer, G. and Kämpfe, D. and Kahl, C. and Vucinic, V. and Monecke, A. and Hirt, C. and Weber, T. and Meissner, J. and Witzens-Harig, M. and Böttcher, S. and Schmalenberg, H. and Marks, R. and Prange-Krex, G. and Kroschinsky, F. and Hauf, E. and Keller, U. and Koch, K. and Klapper, W. and Herold, M. and Scholz, C.W.
Annals of Hematology 99 (12): 2821-2829. December 2020

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes, K. and Hassan, Z.Z. and Doffo, M.J. and Schneeweis, C. and Lier, S. and Öllinger, R. and Rad, R. and Krämer, O.H. and Keller, U. and Saur, D. and Reichert, M. and Schneider, G. and Wirth, M.
Molecular Oncology 14 (12): 3048-3064. December 2020

A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy?
Rieke, D.T. and Keller, U.
Haematologica 105 (11): 2504-2506. 1 November 2020

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Klinghammer, K. and Politz, O. and Eder, T. and Otto, R. and Raguse, J.D. and Albers, A. and Kaufmann, A. and Tinhofer, I. and Hoffmann, J. and Keller, U. and Keilholz, U.
Oncotarget 11 (41): 3688-3697. 13 October 2020

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt, A. and Hassan, Z. and Schneeweis, C. and Schick, M. and Schneider, L. and Muckenhuber, A. and Hong, Y. and Siegers, G. and Nilsson, L. and Wirth, M. and Dantes, Z. and Steiger, K. and Schunck, K. and Langston, S. and Lenhof, H.P. and Coluccio, A. and Orben, F. and Slawska, J. and Scherger, A. and Saur, D. and Müller, S. and Rad, R. and Weichert, W. and Nilsson, J. and Reichert, M. and Schneider, G. and Keller, U.
Gut 69 (8): 1472-1482. August 2020

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes, K. and Hassan, Z. and Doffo, M.J. and Schneeweis, C. and Lier, S. and Öllinger, R. and Rad, R. and Krämer, O.H. and Keller, U. and Saur, D. and Reichert, M. and Schneider, G. and Wirth, M.
bioRxiv : 2020.07.01.182162. 2 July 2020

Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial.
Bröckelmann, P.J. and Goergen, H. and Keller, U. and Meissner, J. and Ordemann, R. and Halbsguth, T.V. and Sasse, S. and Sökler, M. and Kerkhoff, A. and Mathas, S. and Hüttmann, A. and Bormann, M. and Zimmermann, A. and Mettler, J. and Fuchs, M. and von Tresckow, B. and Baues, C. and Rosenwald, A. and Klapper, W. and Kobe, C. and Borchmann, P. and Engert, A.
JAMA Oncology 6 (6): 872-880. June 2020

Final results of a phase I/II trial of the combination Bendamustine and Rituximab with Temsirolimus (BeRT) in relapsed mantle cell lymphoma and follicular lymphoma.
Hess, G. and Wagner, K. and Keller, U. and La Rosee, P. and Atta, J. and Hübel, K. and Lerchenmueller, C. and Schoendube, D. and Witzens-Harig, M. and Ruckes, C. and Medler, C. and van Oordt, C. and Klapper, W. and Theobald, M. and Dreyling, M.
HemaSphere 4 (3): e398. June 2020


Age-related gliosis promotes central nervous system lymphoma through CCL19-mediated tumor cell retention.
O'Connor, T. and Zhou, X. and Kosla, J. and Adili, A. and Garcia Beccaria, M. and Kotsiliti, E. and Pfister, D. and Johlke, A.L. and Sinha, A. and Sankowski, R. and Schick, M. and Lewis, R. and Dokalis, N. and Seubert, B. and Höchst, B. and Inverso, D. and Heide, D. and Zhang, W. and Weihrich, P. and Manske, K. and Wohlleber, D. and Anton, M. and Hoellein, A. and Seleznik, G. and Bremer, J. and Bleul, S. and Augustin, H.G. and Scherer, F. and Koedel, U. and Weber, A. and Protzer, U. and Förster, R. and Wirth, T. and Aguzzi, A. and Meissner, F. and Prinz, M. and Baumann, B. and Höpken, U.E. and Knolle, P.A. and von Baumgarten, L. and Keller, U. and Heikenwalder, M.
Cancer Cell 36 (3): 250-267. 16 September 2019


Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial.
Ferrero, S. and Pastore, A. and Scholz, C.W. and Forstpointner, R. and Pezzutto, A. and Bergmann, L. and Truemper, L. and Finke, J. and Keller, U. and Ghione, P. and Passera, R. and Hiddemann, W. and Weigert, O. and Unterhalt, M. and Dreyling, M.
Leukemia 30 (4): 984-987. April 2016


Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch, K. and Meyer, A.H. and Stroux, A. and Hirt, C. and Keller, U. and Viardot, A. and Marks, R. and Schreiber, S. and Pezzutto, A. and Scholz, C.W.
Annals of Hematology 94 (6): 981-988. June 2015

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.
Philipp-Abbrederis, K. and Herrmann, K. and Knop, S. and Schottelius, M. and Eiber, M. and Lückerath, K. and Pietschmann, E. and Habringer, S. and Gerngroß, C. and Franke, K. and Rudelius, M. and Schirbel, A. and Lapa, C. and Schwamborn, K. and Steidle, S. and Hartmann, E. and Rosenwald, A. and Kropf, S. and Beer, A.J. and Peschel, C. and Einsele, H. and Buck, An.K. and Schwaiger, M. and Götze, K. and Wester, H.J. and Keller, U.
EMBO Molecular Medicine 7 (4): 477-487. 1 April 2015


GP130 activation induces myeloma and collaborates with MYC.
Dechow, T. and Steidle, S. and Götze, K.S. and Rudelius, M. and Behnke, K. and Pechloff, K. and Kratzat, S. and Bullinger, L. and Fend, F. and Soberon, V. and Mitova, N. and Li, Z. and Thaler, M. and Bauer, J. and Pietschmann, E. and Albers, C. and Grundler, R. and Schmidt-Supprian, M. and Ruland, J. and Peschel, C. and Duyster, J. and Rose-John, S. and Bassermann, F. and Keller, U.
Journal of Clinical Investigation 124 (12): 5263-5274. 1 December 2014

Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Hoellein, A. and Fallahi, M. and Schoeffmann, S. and Steidle, S. and Schaub, F.X. and Rudelius, M. and Laitinen, I. and Nilsson, L. and Goga, A. and Peschel, C. and Nilsson, J.A. and Cleveland, J.L. and Keller, U.
Blood 124 (13): 2081-2090. 25 September 2014


Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.
Dörr, J.R. and Yu, Y. and Milanovic, M. and Beuster, G. and Zasada, C. and Däbritz, J.H.M. and Lisec, J. and Lenze, D. and Gerhardt, A. and Schleicher, K. and Kratzat, S. and Purfürst, B. and Walenta, S. and Mueller-Klieser, W. and Gräler, M. and Hummel, M. and Keller, U. and Buck, A.K. and Dörken, B. and Willmitzer, L. and Reimann, M. and Kempa, S. and Lee, S. and Schmitt, C.A.
Nature 501 (7467): 421-425. 19 September 2013

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
Scholz, C.W. and Pinto, A. and Linkesch, W. and Lindén, O. and Viardot, A. and Keller, U. and Hess, G. and Lastoria, S. and Lerch, K. and Frigeri, F. and Arcamone, M. and Stroux, A. and Frericks, B. and Pott, C. and Pezzutto, A.
Journal of Clinical Oncology 31 (3): 308-313. 20 January 2013

This list was generated on Mon Feb 6 02:24:14 2023 CET.
Open Access
MDC Library